Evidence map›Paper›PMID 41722564›Full record

ArticleCell reports. Medicine2026

Dual PD-1/IL-2Rα targeting restores CD8

Xiaoling Shang, Bo Cheng, Zhenxiang Li, Haoyu Wang, Chenyue Zhang, Ning Tang, Liwen Wang, Chenglong Zhao, Jiamao Lin, Haiyong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoling ShangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Bo ChengDepartment of Radiation Oncology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan 250012, China.
Zhenxiang LiDepartment of Radiotherapy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Haoyu WangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Chenyue ZhangDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China.
Ning TangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Liwen WangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Chenglong ZhaoDepartment of Pathology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Jiamao LinDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China. Electronic address: linjiamao_@126.com.
Haiyong WangDepartment of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China. Electronic address: hywang8316@sdfmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMARCA4-deficient non-small cell lung cancer (NSCLC) is a genomically distinct and clinically aggressive subtype characterized by primary resistance to immune checkpoint inhibitors. This study identifies that SMARCA4 deficiency profoundly disrupts the interleukin (IL)-2-STAT5 signaling pathway in tumor-infiltrating CD8

Indexed as

Carcinoma, Non-Small-Cell LungCD47 AntigenCD8-Positive T-LymphocytesDNA HelicasesInterleukin-2 Receptor alpha SubunitLung NeoplasmsNuclear ProteinsProgrammed Cell Death 1 ReceptorSTAT5 Transcription FactorTranscription FactorsAnimalsAntibodies, BispecificCell Line, TumorHumansInterleukin-2MiceAntibodies, BispecificCD47 AntigenDNA HelicasesInterleukin-2Interleukin-2 Receptor alpha SubunitNuclear ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorSMARCA4 protein, humanSTAT5 Transcription FactorTranscription FactorsCD47IL-2immunotherapyNSCLCSMARCA deficiency

Identifiers

PMID41722564
PMCPMC13006401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.